ISB News

ISB Gets $1.7M to Study Cancer Drug Resistance

Congratulations to the Sui Huang Lab at ISB which has received a five-year $1.7 million R01 award from the National Institutes of Health and National Institute for General Medical Sciences to study cancer sub-population dynamics to understand and develop drugs to inhibit lethal cancer-drug resistance. The project proposal states that the work will: “develop a quantitative and formal framework for describing the temporal evolution of cell phenotype distribution in a tumor cell population to address the unmet need to understand how heterogeneity and subpopulation dynamics of tumor cell populations affect drug response.”

Learn more:

Cancer Treatment: A Systems Approach

New Principle of Chemo-Resistance Sheds Light on Cancer Evasiveness

Biggest Family Tree of Human Cells May Help Develop Cell-Replacement Therapies

 


 

Recent Articles

  • 2024 Year in Review

    Reflecting on the past year, ISB has a lot to celebrate: groundbreaking research published in leading scientific journals, well-earned promotions, widespread media coverage, and more. Enjoy our year-in-review roundup highlighting some of the important, interesting, and impactful highlights of 2024.

  • My Digital Gut

    ISB Named Winner of 2024-2025 Amazon Web Services IMAGINE Grant for Nonprofits

    ISB has been selected as a winner of the 2024 Amazon Web Services (AWS) IMAGINE Grant. The grant will support ISB’s continued development of My Digital Gut, an online decision-support platform that will help make microbiome-informed nutrition and healthcare personalized, predictive, and preventive. 

  • ISB-Developed MetaboCore Offers Precision Cancer Care Faster Than Ever 

    ISB Associate Professor Dr. Wei Wei and his colleagues have developed a promising new companion diagnostic tool called MetaboCore to help physicians quickly select the most effective systemic therapy for each cancer patient.